Caseware UK (AP4) 2023.0.135 2023.0.135 2023-12-312023-12-31No description of principal activitytrue2022-07-01false11trueThe members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.false 10257312 2022-07-01 2023-12-31 10257312 2021-07-01 2022-06-30 10257312 2023-12-31 10257312 2022-06-30 10257312 2021-07-01 10257312 c:Director1 2022-07-01 2023-12-31 10257312 d:PlantMachinery 2022-07-01 2023-12-31 10257312 d:PlantMachinery 2023-12-31 10257312 d:PlantMachinery 2022-06-30 10257312 d:PlantMachinery d:OwnedOrFreeholdAssets 2022-07-01 2023-12-31 10257312 d:FurnitureFittings 2022-07-01 2023-12-31 10257312 d:FurnitureFittings 2023-12-31 10257312 d:FurnitureFittings 2022-06-30 10257312 d:FurnitureFittings d:OwnedOrFreeholdAssets 2022-07-01 2023-12-31 10257312 d:OfficeEquipment 2022-07-01 2023-12-31 10257312 d:OfficeEquipment 2023-12-31 10257312 d:OfficeEquipment 2022-06-30 10257312 d:OfficeEquipment d:OwnedOrFreeholdAssets 2022-07-01 2023-12-31 10257312 d:ComputerEquipment 2022-07-01 2023-12-31 10257312 d:ComputerEquipment 2023-12-31 10257312 d:ComputerEquipment 2022-06-30 10257312 d:ComputerEquipment d:OwnedOrFreeholdAssets 2022-07-01 2023-12-31 10257312 d:OwnedOrFreeholdAssets 2022-07-01 2023-12-31 10257312 d:CurrentFinancialInstruments 2023-12-31 10257312 d:CurrentFinancialInstruments 2022-06-30 10257312 d:Non-currentFinancialInstruments 2023-12-31 10257312 d:Non-currentFinancialInstruments 2022-06-30 10257312 d:CurrentFinancialInstruments d:WithinOneYear 2023-12-31 10257312 d:CurrentFinancialInstruments d:WithinOneYear 2022-06-30 10257312 d:Non-currentFinancialInstruments d:AfterOneYear 2023-12-31 10257312 d:Non-currentFinancialInstruments d:AfterOneYear 2022-06-30 10257312 d:Non-currentFinancialInstruments d:BetweenOneTwoYears 2023-12-31 10257312 d:Non-currentFinancialInstruments d:BetweenOneTwoYears 2022-06-30 10257312 d:Non-currentFinancialInstruments d:BetweenTwoFiveYears 2023-12-31 10257312 d:Non-currentFinancialInstruments d:BetweenTwoFiveYears 2022-06-30 10257312 d:ShareCapital 2022-07-01 2023-12-31 10257312 d:ShareCapital 2023-12-31 10257312 d:ShareCapital 2021-07-01 2022-06-30 10257312 d:ShareCapital 2022-06-30 10257312 d:ShareCapital 2021-07-01 10257312 d:RetainedEarningsAccumulatedLosses 2022-07-01 2023-12-31 10257312 d:RetainedEarningsAccumulatedLosses 2023-12-31 10257312 d:RetainedEarningsAccumulatedLosses 2021-07-01 2022-06-30 10257312 d:RetainedEarningsAccumulatedLosses 2022-06-30 10257312 d:RetainedEarningsAccumulatedLosses 2021-07-01 10257312 c:FRS102 2022-07-01 2023-12-31 10257312 c:AuditExempt-NoAccountantsReport 2022-07-01 2023-12-31 10257312 c:FullAccounts 2022-07-01 2023-12-31 10257312 c:PrivateLimitedCompanyLtd 2022-07-01 2023-12-31 10257312 2 2022-07-01 2023-12-31 10257312 d:AcceleratedTaxDepreciationDeferredTax 2023-12-31 10257312 d:AcceleratedTaxDepreciationDeferredTax 2022-06-30 10257312 e:PoundSterling 2022-07-01 2023-12-31 iso4217:GBP xbrli:pure

Registered number: 10257312









EXCELSIOR HEALTH LTD







UNAUDITED

FINANCIAL STATEMENTS

INFORMATION FOR FILING WITH THE REGISTRAR

FOR THE PERIOD ENDED 31 DECEMBER 2023

 
EXCELSIOR HEALTH LTD
REGISTERED NUMBER: 10257312

STATEMENT OF FINANCIAL POSITION
AS AT 31 DECEMBER 2023

31 December
30 June
2023
2022
Note
£
£

Fixed assets
  

Tangible assets
 4 
10,784
7,787

  
10,784
7,787

Current assets
  

Stocks
 5 
325,000
30,000

Debtors: amounts falling due within one year
 6 
140,027
73,505

Cash at bank and in hand
 7 
59,487
64,505

  
524,514
168,010

Creditors: amounts falling due within one year
 8 
(755,510)
(309,125)

Net current liabilities
  
 
 
(230,996)
 
 
(141,115)

Total assets less current liabilities
  
(220,212)
(133,328)

Creditors: amounts falling due after more than one year
 9 
(28,750)
(37,846)

Provisions for liabilities
  

Deferred tax
 11 
(2,696)
(1,479)

  
 
 
(2,696)
 
 
(1,479)

Net liabilities
  
(251,658)
(172,653)


Capital and reserves
  

Called up share capital 
  
100
100

Profit and loss account
  
(251,758)
(172,753)

  
(251,658)
(172,653)


Page 1

 
EXCELSIOR HEALTH LTD
REGISTERED NUMBER: 10257312
    
STATEMENT OF FINANCIAL POSITION (CONTINUED)
AS AT 31 DECEMBER 2023

The director considers that the Company is entitled to exemption from audit under section 477 of the Companies Act 2006 and members have not required the Company to obtain an audit for the period in question in accordance with section 476 of the Companies Act 2006.

The director acknowledges her responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The Company's financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The Company has opted not to file the statement of comprehensive income in accordance with provisions applicable to companies subject to the small companies' regime.

The financial statements were approved and authorised for issue by the board and were signed on its behalf on 16 October 2024.




................................................
S Hundal
Director

The notes on pages 5 to 12 form part of these financial statements.

Page 2

 
EXCELSIOR HEALTH LTD
 

STATEMENT OF CHANGES IN EQUITY
FOR THE PERIOD ENDED 31 DECEMBER 2023


Called up share capital
Profit and loss account
Total equity

£
£
£

At 1 July 2022
100
(172,753)
(172,653)


Comprehensive income for the period

Loss for the period

-
(79,005)
(79,005)


Other comprehensive income for the period
-
-
-


Total comprehensive income for the period
-
(79,005)
(79,005)


Total transactions with owners
-
-
-


At 31 December 2023
100
(251,758)
(251,658)


The notes on pages 5 to 12 form part of these financial statements.

Page 3

 
EXCELSIOR HEALTH LTD
 

STATEMENT OF CHANGES IN EQUITY
FOR THE PERIOD ENDED 30 JUNE 2022


Called up share capital
Profit and loss account
Total equity

£
£
£

At 1 July 2021
100
(48,639)
(48,539)


Comprehensive income for the year

Loss for the year

-
(124,114)
(124,114)


Other comprehensive income for the year
-
-
-


Total comprehensive income for the year
-
(124,114)
(124,114)


Total transactions with owners
-
-
-


At 30 June 2022
100
(172,753)
(172,653)


The notes on pages 5 to 12 form part of these financial statements.

Page 4

 
EXCELSIOR HEALTH LTD
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE PERIOD ENDED 31 DECEMBER 2023

1.


General information

The legal form of the entity is a private company limited by share capital. The company is registered in England and Wales and the trading address is situated at Unit 4 40-40 Link, 30-34 Mill End Road, High Wycombe, Buckinghamshire HP12 4AX

2.Accounting policies

 
2.1

Basis of preparation of financial statements

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with Financial Reporting Standard 102, the Financial Reporting Standard applicable in the UK and the Republic of Ireland and the Companies Act 2006.

The preparation of financial statements in compliance with FRS 102 requires the use of certain critical accounting estimates. It also requires management to exercise judgment in applying the Company's accounting policies.

The following principal accounting policies have been applied:

 
2.2

Foreign currency translation

Functional and presentation currency

The Company's functional and presentational currency is GBP.

Transactions and balances

Foreign currency transactions are translated into the functional currency using the spot exchange rates at the dates of the transactions.

At each period end foreign currency monetary items are translated using the closing rate. Non-monetary items measured at historical cost are translated using the exchange rate at the date of the transaction and non-monetary items measured at fair value are measured using the exchange rate when fair value was determined.

Foreign exchange gains and losses resulting from the settlement of transactions and from the translation at period-end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognised in profit or loss except when deferred in other comprehensive income as qualifying cash flow hedges.

Foreign exchange gains and losses that relate to borrowings and cash and cash equivalents are presented in the Statement of Comprehensive Income within 'finance income or costs'. All other foreign exchange gains and losses are presented in profit or loss within 'other operating income'.

Page 5

 
EXCELSIOR HEALTH LTD
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE PERIOD ENDED 31 DECEMBER 2023

2.Accounting policies (continued)

 
2.3

Revenue

Revenue is recognised to the extent that it is probable that the economic benefits will flow to the Company and the revenue can be reliably measured. Revenue is measured as the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes. The following criteria must also be met before revenue is recognised:

Sale of goods

Revenue from the sale of goods is recognised when all of the following conditions are satisfied:
the Company has transferred the significant risks and rewards of ownership to the buyer;
the Company retains neither continuing managerial involvement to the degree usually associated with ownership nor effective control over the goods sold;
the amount of revenue can be measured reliably;
it is probable that the Company will receive the consideration due under the transaction; and
the costs incurred or to be incurred in respect of the transaction can be measured reliably.

Rendering of services

Revenue from a contract to provide services is recognised in the period in which the services are provided in accordance with the stage of completion of the contract when all of the following conditions are satisfied:
the amount of revenue can be measured reliably;
it is probable that the Company will receive the consideration due under the contract;
the stage of completion of the contract at the end of the reporting period can be measured reliably; and
the costs incurred and the costs to complete the contract can be measured reliably.

 
2.4

Interest income

Interest income is recognised in profit or loss using the effective interest method.

 
2.5

Finance costs

Finance costs are charged to profit or loss over the term of the debt using the effective interest method so that the amount charged is at a constant rate on the carrying amount. Issue costs are initially recognised as a reduction in the proceeds of the associated capital instrument.

 
2.6

Borrowing costs

All borrowing costs are recognised in profit or loss in the period in which they are incurred.

Page 6

 
EXCELSIOR HEALTH LTD
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE PERIOD ENDED 31 DECEMBER 2023

2.Accounting policies (continued)

 
2.7

Current and deferred taxation

The tax expense for the period comprises current and deferred tax. Tax is recognised in profit or loss except that a charge attributable to an item of income and expense recognised as other comprehensive income or to an item recognised directly in equity is also recognised in other comprehensive income or directly in equity respectively.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the Company operates and generates income.

Deferred tax balances are recognised in respect of all timing differences that have originated but not reversed by the reporting date, except that:
The recognition of deferred tax assets is limited to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits; and
Any deferred tax balances are reversed if and when all conditions for retaining associated tax allowances have been met.

Deferred tax balances are not recognised in respect of permanent differences except in respect of business combinations, when deferred tax is recognised on the differences between the fair values of assets acquired and the future tax deductions available for them and the differences between the fair values of liabilities acquired and the amount that will be assessed for tax. Deferred tax is determined using tax rates and laws that have been enacted or substantively enacted by the reporting date.


 
2.8

Tangible fixed assets

Tangible fixed assets under the cost model are stated at historical cost less accumulated depreciation and any accumulated impairment losses. Historical cost includes expenditure that is directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management.

Depreciation is charged so as to allocate the cost of assets less their residual value over their estimated useful lives, using the straight-line method.

Depreciation is provided on the following basis:

Plant and machinery
-
20%
Fixtures and fittings
-
20%
Office equipment
-
20%

The assets' residual values, useful lives and depreciation methods are reviewed, and adjusted prospectively if appropriate, or if there is an indication of a significant change since the last reporting date.

Gains and losses on disposals are determined by comparing the proceeds with the carrying amount and are recognised in profit or loss.

Page 7

 
EXCELSIOR HEALTH LTD
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE PERIOD ENDED 31 DECEMBER 2023

2.Accounting policies (continued)

 
2.9

Stocks

Stocks are stated at the lower of cost and net realisable value, being the estimated selling price less costs to complete and sell. Cost is based on the cost of purchase on a first in, first out basis. Work in progress and finished goods include labour and attributable overheads.

At each reporting date, stocks are assessed for impairment. If stock is impaired, the carrying amount is reduced to its selling price less costs to complete and sell. The impairment loss is recognised immediately in profit or loss.

 
2.10

Debtors

Short-term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment.

 
2.11

Cash and cash equivalents

Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.

 
2.12

Creditors

Short-term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.

 
2.13

Provisions for liabilities

Provisions are recognised when an event has taken place that gives rise to a legal or constructive obligation, a transfer of economic benefits is probable and a reliable estimate can be made.
Provisions are measured as the best estimate of the amount required to settle the obligation, taking into account the related risks and uncertainties.
 
Increases in provisions are generally charged as an expense to profit or loss.


3.


Employees

The average monthly number of employees, including the director, during the period was as follows:


        2023
        2022
            No.
            No.







Director
1
1

Page 8

 
EXCELSIOR HEALTH LTD
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE PERIOD ENDED 31 DECEMBER 2023

4.


Tangible fixed assets







Plant and machinery
Fixtures and fittings
Office equipment
Computer equipment
Total

£
£
£
£
£



Cost or valuation


At 1 July 2022
-
8,597
470
841
9,908


Additions
3,103
2,007
-
-
5,110


Disposals
-
-
-
(840)
(840)



At 31 December 2023

3,103
10,604
470
1
14,178



Depreciation


At 1 July 2022
-
1,211
69
841
2,121


Charge for the period on owned assets
236
1,783
94
(840)
1,273



At 31 December 2023

236
2,994
163
1
3,394



Net book value



At 31 December 2023
2,867
7,610
307
-
10,784



At 30 June 2022
-
7,386
401
-
7,787


5.


Stocks

31 December
30 June
2023
2022
£
£

Finished goods and goods for resale
325,000
30,000

325,000
30,000



6.


Debtors

31 December
30 June
2023
2022
£
£


Trade debtors
26,316
19,282
Page 9

 
EXCELSIOR HEALTH LTD
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE PERIOD ENDED 31 DECEMBER 2023

6.Debtors (continued)


Other debtors
113,711
42,140

Prepayments and accrued income
-
12,083

140,027
73,505



7.


Cash and cash equivalents

31 December
30 June
2023
2022
£
£

Cash at bank and in hand
59,487
64,505

59,487
64,505



8.


Creditors: Amounts falling due within one year

31 December
30 June
2023
2022
£
£

Bank loans
6,360
5,472

Trade creditors
366,749
130,278

Amounts owed to group undertakings
80,593
156,594

Corporation tax
6,611
-

Other creditors
291,732
14,186

Accruals and deferred income
3,465
2,595

755,510
309,125



9.


Creditors: Amounts falling due after more than one year

31 December
30 June
2023
2022
£
£

Bank loans
28,750
37,846

28,750
37,846


Page 10

 
EXCELSIOR HEALTH LTD
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE PERIOD ENDED 31 DECEMBER 2023

10.


Loans


Analysis of the maturity of loans is given below:


31 December
30 June
2023
2022
£
£

Amounts falling due within one year

Bank loans
6,360
5,472


6,360
5,472

Amounts falling due 1-2 years

Bank loans
6,360
5,472


6,360
5,472

Amounts falling due 2-5 years

Bank loans
22,390
32,374


22,390
32,374


35,110
43,318



11.


Deferred taxation






2023


£






At beginning of year
(1,480)


Charged to profit or loss
(1,216)



At end of year
(2,696)

Page 11

 
EXCELSIOR HEALTH LTD
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE PERIOD ENDED 31 DECEMBER 2023
 
11.Deferred taxation (continued)

The provision for deferred taxation is made up as follows:

31 December
30 June
2023
2022
£
£


Accelerated capital allowances
(2,696)
(1,480)

(2,696)
(1,480)

 
Page 12